Dr. Carlos Manuel Decastro III, MD

Dr. Decastro practices at Duke University Hospital in Durham, North Carolina, part of Duke University.

Dr. Decastro's NPI, 1912080169, was assigned on October 23, 2006. Dr. Decastro graduated from University of Texas Southwestern Medical School at Dallas in 1985. Dr. Decastro holds North Carolina license 33980.

Dr. Decastro's primary practice is Duke University Hospital, at 2301 Erwin Rd, Durham, NC 27705 in Durham County. The practice phone is (919) 684-8111.

Dr. Decastro's primary practice is Duke University Hospital in Durham, North Carolina, part of Duke University. Dr. Decastro is also affiliated with Duke Regional Hospital. The medical group on file is Duke Health Integrated Practice. Dmand AI also links Dr. Decastro to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Decastro practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Decastro's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Decastro is licensed in North Carolina.

CMS data shows 578 Medicare services from Dr. Decastro across 4 procedure codes in 2024, for 161 Medicare patients. Medicare paid $27,321 for them. Every service was in an office.

CMS counts 161 Medicare patients who saw Dr. Decastro in 2024. The largest group is 65 to 74, with 71 patients. 73% of them have high blood pressure, and 68% have high cholesterol. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Decastro's median patient age at 75, with 48% women.

In 2024, Dr. Decastro wrote 410 Medicare Part D claims for 63 patients. 55% of them were for generic drugs. CMS names the drug for 273 of them, across 13 drugs with 11 or more claims each, at $2,516,776 in total drug cost. In 2023, CMS named 220 claims across 10 drugs.

Dr. Decastro accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Decastro as offering telehealth.

Dmand AI links Dr. Decastro to 1 clinical trial. Conditions studied include Leukemia, Myelomonocytic, Chronic and Myelodysplastic-Myeloproliferative Diseases. Open Payments lists research payments to Dr. Decastro that name 2 trials.

CMS Open Payments shows 105 general payments to Dr. Decastro from 13 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 47% of the total. Alexion Pharmaceuticals, Inc. paid the most, $58,985. It also lists 17 research payments totaling $33,528 from 2016 to 2025, naming 2 clinical trials.

Dr. Decastro graduated from University of Texas Southwestern Medical School at Dallas in 1985.